​​​​​​​EuroBiotech:​​​ ​​​More​​​ ​​​Articles​​​ ​​​of​​​ ​​​Note


> Galapagos unveiled Dr. Walid Abi-Saab as its CMO. Abi-Saab joins Galapagos from Shire, where he rose to the role of therapeutic area head for gastrointestinal, endocrinology and metabolism conditions. Prior to joining Shire, Abi-Saab worked on clinical development at companies including Abbott Laboratories, Novartis and Pfizer. Release

> Shares in NeuroVive Pharmaceutical rose 70% after it posted preclinical data in hepatocellular cancer. The Swedish biotech said some of its sanglifehrin-based compounds “exert unexpectedly potent anticancer effects” in preclinical. With NeuroVive’s share price at a low ebb following failures in the clinic, the early-stage data were enough to spark a surge in its value. Release

> Malin invested in Wren Therapeutics, a spinout of the University of Cambridge, UK, and Lund University, Sweden. Wren is looking at protein misfolding diseases using a platform that emerged from research at the two academic centers. Malin, an investment fund helmed by Kelly Martin, has a 33% stake in Wren, and an option to up its holding to 67%. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Zealand Pharma received $10 million (€9 million) from Sanofi after the European Union approved Suliqua. The milestone stems from a deal that gave Sanofi access to Zealand’s GLP-1 analogue lixisenatide. Zealand is eligible to receive up to $100 million more in milestones. Release

> FDA granted rare pediatric disease designation to Lysogene’s LYS-GM101 in the neurodegenerative disease GM1 gangliosidosis. LYS-GM101 is a gene therapy designed to equip people to produce their own lysosomal acid beta-balactosidase enzyme, and, in doing so, stop the neurological damage caused by the condition. Release

> CellProthera raised €8.3 million ($8.9 million) to continue its phase 1/2b trials and prepare for a phase 3 study. The preparations for the phase 3 will entail setting up cell therapy centers in Europe, the U.S. and Canada. CellProthera is focused on using autologous stem cells to regenerate the heart following acute myocardial infarction. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.